The double face of IL-1β in lung cancer

OncoImmunology 2026 Open access

Read full text
Authors: Cédric Rébé, Anaïs Perrichet, François Ghiringhelli
DOI: 10.1080/2162402x.2026.2622661
Cited by: 0
References: 15

Abstract

Interleukin (IL)-1β is known to promote lung cancer growth in both humans and mice. However, in the context of the current standard of care, which includes chemotherapy and immune checkpoint inhibitors, IL-1β can overcome resistance.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Cytokine Signaling Pathways and Interactions IL-33 ST2 and ILC Pathways

Publication details

Journal / source
OncoImmunology
Volume
15
Issue
1
Pages
2622661–2622661
Publication date
3 February 2026
Language
EN